JP2023507142A - 多重特異性ｔ細胞受容体 - Google Patents

多重特異性ｔ細胞受容体 Download PDF

Info

Publication number
JP2023507142A
JP2023507142A JP2022537047A JP2022537047A JP2023507142A JP 2023507142 A JP2023507142 A JP 2023507142A JP 2022537047 A JP2022537047 A JP 2022537047A JP 2022537047 A JP2022537047 A JP 2022537047A JP 2023507142 A JP2023507142 A JP 2023507142A
Authority
JP
Japan
Prior art keywords
mhc
tcr
recognizes
antigen
supertopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507142A5 (enExample
Inventor
フルー、クラウス
ピッカー、ルイス
サチャ、ジョナー
ハンセン、スコット
ビンバー、ベンジャミン
アブドゥルハク、シャヒード
Original Assignee
オレゴン ヘルス アンド サイエンス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ヘルス アンド サイエンス ユニバーシティ filed Critical オレゴン ヘルス アンド サイエンス ユニバーシティ
Publication of JP2023507142A publication Critical patent/JP2023507142A/ja
Publication of JP2023507142A5 publication Critical patent/JP2023507142A5/ja
Priority to JP2025169565A priority Critical patent/JP2026010019A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022537047A 2019-12-16 2020-12-15 多重特異性ｔ細胞受容体 Pending JP2023507142A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025169565A JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962948691P 2019-12-16 2019-12-16
US62/948,691 2019-12-16
PCT/US2020/065147 WO2021126872A1 (en) 2019-12-16 2020-12-15 Multi-specific t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025169565A Division JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Publications (2)

Publication Number Publication Date
JP2023507142A true JP2023507142A (ja) 2023-02-21
JP2023507142A5 JP2023507142A5 (enExample) 2023-12-13

Family

ID=76476722

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537047A Pending JP2023507142A (ja) 2019-12-16 2020-12-15 多重特異性ｔ細胞受容体
JP2025169565A Pending JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025169565A Pending JP2026010019A (ja) 2019-12-16 2025-10-07 多重特異性ｔ細胞受容体

Country Status (8)

Country Link
US (1) US20230272036A1 (enExample)
EP (1) EP4076510A4 (enExample)
JP (2) JP2023507142A (enExample)
KR (1) KR20220116458A (enExample)
CN (1) CN114828877A (enExample)
AU (1) AU2020404933A1 (enExample)
CA (1) CA3161826A1 (enExample)
WO (1) WO2021126872A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531745A (ja) * 2016-10-18 2019-11-07 オレゴン ヘルス アンド サイエンス ユニバーシティ 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507843A (ja) * 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
CA3091954A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh New ehv with inactivated ul18 and/or ul8

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531745A (ja) * 2016-10-18 2019-11-07 オレゴン ヘルス アンド サイエンス ユニバーシティ 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C-Y. ZHOU, ET AL., JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 20, no. 10, JPN6024046733, 2016, pages 1984 - 1998, ISSN: 0005614002 *

Also Published As

Publication number Publication date
JP2026010019A (ja) 2026-01-21
CN114828877A (zh) 2022-07-29
AU2020404933A1 (en) 2022-06-30
WO2021126872A1 (en) 2021-06-24
EP4076510A4 (en) 2024-01-10
EP4076510A1 (en) 2022-10-26
US20230272036A1 (en) 2023-08-31
KR20220116458A (ko) 2022-08-23
CA3161826A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US20240052010A1 (en) Methods of obtaining tumor-specific t cell receptors
US11305015B2 (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
JP2022166122A (ja) 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
KR20230079259A (ko) Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도
US20260041750A1 (en) Vaccine constructs comprising tuberculosis antigens
Ruffini et al. Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines
JP2003512844A (ja) 多発性硬化症関連スーパー抗原
JP2026010019A (ja) 多重特異性ｔ細胞受容体
JP2022544704A (ja) ヒトサイトメガロウイルスのｕｌ１８によるｔ細胞応答の調節
HK40076198A (en) Multi-specific t cell receptors
Li et al. Identification and characterization of Th cell epitopes in MrkD adhesin of Klebsiella pneumoniae
JP2002524469A (ja) ワクチンアジュバントとしてのコレラ毒素ｂまたは腸毒素ｂのペプチドフラグメント
Mizuno et al. Characterization of a Novel Transmembrane Activating STING Agonist using Genetically Humanized Mice
US20260091102A1 (en) Universal t cell-based, cmv-vectored vaccine for influenza
CN120712104A (zh) 针对神经胶质瘤的肽疫苗及其用途
HK40011160A (zh) 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
JPH11514968A (ja) 筋無力症の処置のためのヌクレオチドおよびペプチド配列

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250610